TLR4 and systemic sclerosis: In the development of drugs targeting S100A9, Paquinimod, which blocked its interaction with RAGE and TLR4, has already reached Phase II clinical trials for the treatment of systemic sclerosis, demonstrating promising efficacy and safety.[24] Our study further sheds likely light on the development of novel treatment strategy for PH.